Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort studyResearch in context

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort studyResearch in context

Summary: Background: As most people now have established hybrid immunity, the need for regular, updated SARS-CoV-2 vaccine boosters in patients with immune-mediated inflammatory diseases (IMIDs) is unclear. The study aim was to assess humoral and cellular immunogenicity of a fifth bivalent vaccine...

Full description

Saved in:
Bibliographic Details
Main Authors: Hilde S. Ørbo, Taissa de Matos Kasahara, Asia-Sophia Wolf, Kristin H. Bjørlykke, Joseph Sexton, Ingrid Jyssum, Anne T. Tveter, Guri Solum, Ingrid Fadum Kjønstad, Sabin Bhandari, Ingrid E. Christensen, Tore K. Kvien, Andreas Lind, Hassen Kared, Jørgen Jahnsen, Espen A. Haavardsholm, Ludvig A. Munthe, Sella A. Provan, John T. Vaage, Siri Mjaaland, Silje Watterdal Syversen, Kristin K. Jørgensen, Gunnveig Grødeland, Guro Løvik Goll
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:The Lancet Regional Health. Europe
Subjects:
SARS-CoV-2
Vaccination
COVID-19
TNF inhibitors
Tumour necrosis factor inhibitor
T cells
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776224002898
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items